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Factors Associated with Undiagnosed Obstructuve Sleep Apnea in Hypertensive
Primary Care Patients
Abstract
Objective. In hypertensive primary care patients below 65 years of age, (i) to describe the occurrence of
undiagnosed obstructive sleep apnoea (OSA), and (ii) to identify the determinants of moderate/severe
OSA. Design. Cross-sectional. Setting. Four primary care health centres in Sweden. Patients. 411
consecutive patients (52% women), mean age 57.9 years (SD 5.9 years), with diagnosed and treated
hypertension (BP >140/90). Main outcome measures. Occurrence of OSA as measured by the apnoea
hypopnoea index (AHI). Results. Mild (AHI 5–14.9/h) and moderate/severe (AHI > 15/h) OSA were seen
among 29% and 30% of the patients, respectively. Comparing those without OSA with those with mild or
moderate/severe OSA, no differences were found in blood pressure, pharmacological treatment (antihypertensive, anti-depressive, and hypnotics), sleep, insomnia symptoms, daytime sleepiness, or
depressive symptoms. Obesity (BMI > 30 kg/m2) was seen in 30% and 68% of the patients with mild and
moderate/severe OSA, respectively. Male gender, BMI > 30 kg/m2, snoring, witnessed apnoeas, and sleep
duration >8 hours were determinants of obstructive sleep apnoea. Conclusion. Previously undiagnosed
OSA is common among patients with hypertension in primary care. Obesity, snoring, witnessed apnoeas,
long sleep duration, and male gender were the best predictors of OSA, even in the absence of daytime
sleepiness and depressive symptoms.
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ORIGINAL ARTICLE

Factors associated with undiagnosed obstructive sleep apnoea in
hypertensive primary care patients
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Abstract
Objective. In hypertensive primary care patients below 65 years of age, (i) to describe the occurrence of undiagnosed
obstructive sleep apnoea (OSA), and (ii) to identify the determinants of moderate/severe OSA. Design. Cross-sectional.
Setting. Four primary care health centres in Sweden. Patients. 411 consecutive patients (52% women), mean age 57.9 years
(SD 5.9 years), with diagnosed and treated hypertension (BP ⬎ 140/90). Main outcome measures. Occurrence of OSA
as measured by the apnoea hypopnoea index (AHI). Results. Mild (AHI 5–14.9/h) and moderate/severe (AHI ⬎ 15/h)
OSA were seen among 29% and 30% of the patients, respectively. Comparing those without OSA with those with mild or
moderate/severe OSA, no differences were found in blood pressure, pharmacological treatment (anti-hypertensive,
anti-depressive, and hypnotics), sleep, insomnia symptoms, daytime sleepiness, or depressive symptoms. Obesity (BMI
⬎ 30 kg/m2) was seen in 30% and 68% of the patients with mild and moderate/severe OSA, respectively. Male gender,
BMI ⬎ 30 kg/m2, snoring, witnessed apnoeas, and sleep duration ⬎ 8 hours were determinants of obstructive sleep apnoea.
Conclusion. Previously undiagnosed OSA is common among patients with hypertension in primary care. Obesity, snoring,
witnessed apnoeas, long sleep duration, and male gender were the best predictors of OSA, even in the absence of daytime
sleepiness and depressive symptoms.
Key Words: Depression, hypertension, obstructive sleep apnoea, sleep, sleep disordered breathing, snoring

Background
Hypertension (HT) is a common but treatable risk
factor for cardiovascular disease (CVD) and ischaemic heart disease (IHD). The prevalence of HT has
been estimated to be approximately 30% in the
United States and 40% in European countries [1].
Studies show that obstructive sleep apnoea (OSA)
occurs in up to one-quarter of men and women in
the general population [2–5] when defined as at least
five respiratory pauses (i.e. apnoeas and hypopnoeas)
per hour of sleep. It is linked to HT, CVD, IHD, and

mortality [6,7]. A proposed mechanism is the
increased cardiovascular stress (i.e. sympathetic activation) caused by the respiratory disturbance [6].
Another link is the shared prevalence of obesity [8].
Obesity is significantly less prevalent in Sweden than
in the United States, where most studies of OSA and
HT have been conducted. However, recent Swedish
data indicate an increasing obesity problem [9], which
might increase the occurrence of OSA. Depression
and sleep complaints are other prevalent problems
in primary care. Both are associated with OSA in
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Current awareness:
• Obstructive sleep apnoea has been linked to
hypertension in sleep clinic populations, but
there is a lack of knowledge regarding the
occurrence in Swedish hypertensive primary
care patients.
Main statements:
• Undiagnosed mild and moderate/severe
obstructive sleep apnoea was seen among
29% and 30% of patients, respectively.
• Comparing subjects with mild or moderate/
severe obstructive sleep apnoea with those
without, no differences were found in blood
pressure, self-rated sleep duration, insomnia,
daytime sleepiness, or depressive symptoms.
• Male gender, BMI ⬎ 30 kg/m00B2, snoring, witnessed apnoeas, and sleep duration
⬎ 8 hours were determinants of moderate/
severe obstructive sleep apnoea in hypertensive
primary care patients.

patients referred to sleep clinics and in the general
population with poor health perceptions [10].
Two previous Swedish studies [11,12] have investigated the prevalence of OSA in hypertensive
patients. Sjöström et al. [11] found that 37% of
middle-aged men had mild OSA and Hedner et al.
[12] found a prevalence of 83% having mild OSA in
patients with both HT and diabetes. However,
metabolic syndrome is one of the best predictors
for OSA [13], which might affect the prevalence.
Furthermore, none of these studies investigated the
association of OSA with sleep complaints, depression, and self-rated health, all plausible predictors of
undiagnosed OSA in a primary care setting. The aim
of the present study was to (i) describe the occurrence
of undiagnosed obstructive sleep apnoea (OSA), and
(ii) identify the determinants of moderate/severe
OSA in hypertensive primary care patients below
65 years of age.

Material and methods
Design and selection criteria
A cross-sectional design was used. After ethical
approval (M29 - 07), all 918 eligible patients 18–65
years of age with diagnosed hypertension (140/90
mmHg) at four primary care centres in Sweden were
screened. Exclusion criteria were terminal disease,
ongoing treatment for OSA, severe psychiatric disease,

dementia, alcohol/drug abuse, or difficulties reading
and understanding the Swedish language.
Clinical variables
Data regarding weight, height, blood pressure, subjective sleep (i.e. sleep duration, estimated sleep
need), medication, and comorbidities were collected
during a clinical examination. Diagnosis of diabetes
mellitus was based on history, current treatment
(oral therapy or insulin), or repeated fasting blood
glucose values ⱖ 7mmol/l. IHD was defined as a history of angina pectoris and/or myocardial infarction
and/or coronary angioplasty and/or coronary bypass
surgery. Respiratory disease was defined as a history
of asthma or chronic obstructive pulmonary disease,
or on current treatment (β2 agonists and/or inhaled
corticosteroids).
Self-rating scales
The Berlin Sleep Apnea Questionnaire (BSAQ) (11
items), focusing on occurrence of OSA symptoms/
characteristics, was used to measure the risk of having OSA [14]. The Minimal Insomnia Symptoms
Scale (three items) was used to measure difficulties
initiating sleep, difficulties maintaining sleep, and
difficulties with non-restorative sleep [15].The patients
grade their difficulties on a scale ranging from no
problems (0), to very great problems (4). The
Epworth sleepiness scale was used to measure excessive daytime sleepiness (EDS) [16]. The total score
of the eight items ranged from 0 to 24 points, with
a cut-off of ⬎ 10 indicating EDS. The Hospital Anxiety and Depression scale (HAD) (14 items) was
used to measure depressive symptoms [17]. The total
score of the seven depression items range from 0 to
21; the higher the score the more depressive symptoms. A cut-off of ⬎ 7 was used to indicate depressive symptoms. The first question concerning current
health status from the SF-36 was used to measure
perceived health [18]. The participants ranked their
health as (1) excellent, (2) very good, (3) good, (4)
fair, or (5) poor.

Recordings of sleep disordered breathing
Full-night respiratory recordings with monitoring of
nasal airflow, pulse oximetry, respiratory movements,
and body position were performed in the patients’
homes using polygraphic equipment [19] (Embletta,
ResMed AB, Trollhättan, Sweden). Apnoeas and
hypopnoeas were manually scored. An apnoea was
scored if the nasal pressure signal amplitude dropped
ⱖ 90% for ⬎ 10 seconds and 90% of the event met
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amplitude reduction criteria. A hypopnoea was
scored if the nasal pressure signal amplitude dropped
ⱖ 30%, oxygen-saturation dropped ⱖ 4% for ⬎ 10
seconds and 90% of the events met amplitude reduction criteria. Sleep time was estimated from sleep-log
and trace patterns. Recordings were scored by the
second author blinded to the other data. The total
number of apnoeas and hypopnoeas was divided by
the estimated sleep time giving the apnoea–hypopnoea
index (AHI). An oxygen-desaturation index (ODI)
was calculated in the same manner based on desaturations of ⬎ 4%. Patients were defined as having mild
OSA or moderate/severe OSA if they had AHI
5–14.9/h or ⬎ 15/h, respectively.
Statistical analysis
Categorical data were described with percentages
and numbers, whereas continuous data were described
with means and 95% confidence interval. Normally
distributed variables were analysed with a t-test,
ANOVA, or Pearson correlations. A Mann–Whitney
test, Kruskal–Wallis test, chi-squared test, or Spearman rank correlations were used on non-normally
distributed or dichotomous variables. To examine
variables independently associated with AHI ⬎15,
logistic regression analysis was used. Based on bivariate
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correlations, variables with an association of p ⬍ 0.20
with AHI ⬎ 15 were entered as predictors into a
multiple logistic regression. The significance level
was set to p ⬍ 0.05. All statistical analyses were performed with the PASW statistics 18 (IBM Inc.,
USA).

Results
Study population
Of the 918 patients, 12% (50 men/59 women) were
excluded and 28% (170 men/159 women) chose not
to participate. Of the 480 patients who participated
in the clinical examination, 411 had a respiratory
recording although 17 were lost due to technical
problems (Figure 1). Thus, the final study population
consisted of 394 patients. Population characteristics,
comorbidities, and medications are given in Table I.
Occurrence of OSA
It total, 59% of the 394 patients had OSA (AHI ⬎ 5).
Mild and moderate/severe OSA occurred among 29%
and 30% of the patients, respectively. Average ODI
was four and 16 times as high in the groups with mild
and moderate/severe OSA (7.9 and 32.0, respectively)

Step 1: Screening of patients at 4 hypertension clinics
Eligible: 918 pts
Excluded: 109 pts
Causes for exclusion: terminal disease: 8 pts, ongoing treatment for OSA: 17 pts, severe psychiatric disease: 11
pts, dementia: 8 pts, alcohol/drug abuse: 52 pts, difficulties understanding/reading Swedish: 13 pts
Did not want to participate: 329 pts

Step 2: Clinical assessment and self-rating scales
Eligible: 480 pts were assessed regarding weight, height, and blood pressure. Data regarding medication and
comorbidities were collected. Self-rating scales for OSA symptoms, sleep, insomnia, daytime sleepiness,
depressive symptoms, and perceived health were answered.
Did not want to perform polygraphy: 69 pts

Step 3: Respiratory recordings during sleep
Eligible: 411 pts were screened for OSA with a full night polygraphy
Excluded: 17 pts
Causes for exclusion: recording failures: 10 pts, patients could not accept the equipment: 7 pts
Final study population: 394 pts

Figure 1. Description of design, and number of eligible and excluded patients in the study.
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Table I. Characteristics, medication, and comorbidities across the severity groups for obstructive sleep apnoea in hypertensive
primary care patients below 65 years of age (n ⫽ 394).
AHI

Characteristics
Gender: n (%, CI 95%)
Men
Age: m [SD] (CI 95%)
Sleep-disordered breathing:
m [SD] (CI 95%)
Apnoea–hypopnoea index
Oxygen desaturation index
SaO2 – M
SaO2 – N
Total desaturations
Time ⬍ 90%
Blood pressure: m [SD] (CI 95%)
Systolic blood pressure
Diastolic blood pressure
BMI (kg/m2): m [SD] (CI 95%)
Medication: n (%, CI 95%)
CA blockers
Beta-blockers
ACEI/ARB
Digoxin
Diuretics
Number of hypertensive drugs,
m [SD] (CI 95%)
Hypnotics
Antidepressants
Comorbidities: n (%, CI 95%)
Diabetes
Ischaemic heart disease
Hypercholesterolemia
Respiratory disease
TIA/stroke

⬍ 5/h No obstructive sleep
apnoea n ⫽ 160, 41%

5–14.9/h Mild obstructive
sleep apnoea n ⫽ 113, 29%

ⱖ 15/h Moderate/severe
Obstructive sleep apnoea
n ⫽ 121, 30%

60 (38, 31–46)
57.3 [6.7] (56.3–58.4)

57 (50, 40–59)
57.8 [7.6] (56.4–59.1)

69 (58, 49–66)
58.8 [5.8] (57.4–59.5)

2.1 [1.5]
2.0 [1.5]
94.4 [7.4]
88.7 [7.4]
13.8 [12.2]
0.5 [4.7]

(1.9–2.3)
(1.7–2.2)
(93.2–95.6)
(87.5–89.9)
(11.8–15.7)
(0–1.3)

8.8 [2.7]
7.9 [3.1]
94.0 [3.8]
84.2 [8.6]
52.4 [24.0]
1.4 [4.8]

(8.3–9.3)
(7.3–8.5)
(93.3–94.8)
(82.6–85.9)
(47.9–57.0)
(0.5–2.31)

138.8 [17.4] (136.0–141.5)
86.4 [9.5] (84.9–87.9)
27.0 [4.2] (26.4–27.7)

142.8 [15.8] (139.9–145.7)
87.8 [10.1] (85.9–89.7)
29.1 [4.8] (28.2–30.0)

27 (17, 11–23)
72 (46, 38–54)
90 (57, 50–65)
0
50 (32, 25–39)
1.5 [0.8] (1.4–1.7)
10 (6, 3–10)
10 (6, 2–10)

23 (20, 13–27)
51 (44, 35–53
68 (59, 50–68)
0
37 (32, 24–41)
1.5 [0.9] (1.4–1.7)
4 (4, 1–7)
15 (13, 7–19)

20
112
40
10
3

(22, 8–18)
(72, 65–79)
(26, 19–33)
(6, 3–10)
(2, 0–3)

22
82
33
6
2

(20, 12–27)
(72, 64–80)
(29, 21–38)
(5, 1–9)
(2, 0–2)

34.7 [19.1]
32.0 [19.2]
93.1 [1.7]
77.0 [11.5]
195.2 [134.4]
10.6 [13.4]

(31.2–38.3)
(28.5–35.5)
(92.7–93.4)
(74.9–79.1)
(170.6–219.8)
(8.12–13.0)

140.6 [18.5] (137.1–143.8)
87.5 [12.0] (85.4–89.7)
30.8 [5.1] (29.8–31.7)
30
61
68
1
42
1.7 [0.8]
4
13

(25, 16–31)
(51, 42–60)
(56, 48–66)
(0)
(35, 26–44)
(1.5–1.8)
(3, 1–6)
(11, 5–16)

25
92
41
8
3

(21, 14–29)
(77, 70–85)
(35, 27–44)
(7, 2–11)
(3, 0–3)

Note: The AASM criteria were used when hypertensive primary care patients below 65 years of age were categorized into OSA groups
based on apnea–hypopnea index ⬍ 5/h, 5–14.9/h, or ⱖ 15/h.
Key: ACEI ⫽ angiotensin converting inhibitor; ARB ⫽ angiotensin receptor blockers; AHI ⫽ apnea–hypopnea index; B-blockers ⫽ betablockers; BMI ⫽ body mass index; CI 95% ⫽ 95% confidence interval; DBP ⫽ diastolic blood pressure; HC ⫽ hypercholesterolemia,
IHD ⫽ ischaemic heart disease; n ⫽ numbers; m ⫽ mean; ODI ⫽ oxygen desaturation index; RD ⫽ respiratory disease; SaO2 – M ⫽ mean
saturation, SaO2 – N ⫽ nadir saturation, SBP ⫽ systolic blood pressure; TIA/stroke ⫽ transient ischaemic attack/stroke.

compared with those without OSA (2.0) (see Table I).
Neither systolic or diastolic blood pressure or medication differed between the two groups of patients with
OSA, or compared with patients without OSA. BMI
was significantly associated with AHI. Obesity (BMI
⬎ 30 kg/m2) was seen in 30% and 68% of the patients
with mild and moderate/severe OSA, respectively.
Diabetes was significantly more prevalent among
patients with at least mild OSA. Neither history of
IHD nor respiratory disease was associated with
severity of OSA (see Table I).
Differences among OSA groups and determinants
of OSA
No differences were found regarding estimated
sleep need, sleep sufficiency index, insomnia, EDS,

or depressive symptoms with regard to different
degrees of OSA (Table II). The choice of variables
included in the regression analysis was based on
their bivariate relationship to OSA (AHI ⬎15). In
the final analysis only male gender, BMI ⬎30 kg/m2,
snoring, reports of witnessed apnoeas, and sleep
duration ⬎8 hours were significant determinants of
OSA (AHI ⱖ15). Specifically, men had 1.7 times
the odds of having moderate/severe OSA; BMI
⬎30 kg/m2 presented 4.0 times the odds; snorers
had 3.9 times the odds; witnessed apnoeic events
3.2 times the odds; and sleep duration ⬎8 hours
had 3.6 times the odds of OSA in this sample
(Table III). Age, daytime sleepiness, diabetes,
hypercholesterolemia, perceived health, or depressive symptoms were not significant indicators of
OSA in this sample.
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Table II. Self-rated sleep, daytime sleepiness, depressive symptoms, and perceived health across the severity groups for
obstructive sleep apnoea in hypertensive primary care patients below 65 years of age (n ⫽ 394).
AHI

Characteristics
Self-rated sleep: m [SD] (CI 95%)
Sleep duration, hours
Estimated sleep need, hours
Sleep sufficiency index, %
Self-rated symptoms of obstructive sleep apnoea:
High risk BSAQ, n (%, CI 95%)
Snoring, n (%, CI 95%)
Witnessed apnoeas, n (%, CI 95%)
Insomnia symptoms: n (%, CI 95%)
Difficulties initiating sleep
Difficulties maintaining sleep
Difficulties with non-restorative sleep
Daytime sleepiness:
Total ESS score, m [SD] (CI 95%)
ESS ⬎ 10, n (%, CI 95%))
Depressive symptoms:
HAD total score, m [SD] (CI 95%)
Yes (HAD ⬎ 7), n (%, CI 95%)
Perceived health: m [SD] (CI 95%)

⬍ 5/h
No obstructive sleep
apnoea
n ⫽ 160, 41%

5–14.9/h
Mild obstructive sleep
apnoea
n ⫽ 113, 29%

ⱖ 15/h
Moderate/severe
obstructive sleep apnoea
n ⫽ 121, 30%

6.7 [0.9] (6.5–6.8)
7.6 [0.7] (7.5–7.7)
0.88 [0.1] (0.86–0.90)

6.6 [1.1] (6.4–6.8)
7.8 [0.9] (7.6–8.0)
0.85 [0.1] (0.82–0.88)

7.0 [1.1] (6.8–7.2)
7.9 [1.0] (7.7–8.1)
0.89 [0.1] (0.86–0.91)

92 (60, 52–67)
102 (76, 69–83)
13 (8, 4–13)

95 (84, 77–90)
97 (91, 85–96)
20 (18, 11–25)

108 (91, 86–96)
113 (97, 93–99)
44 (11, 28–45)

36 (23, 17–30)
73 (47, 39–55)
68 (45, 37–53)

40 (34, 26–44)
68 (60, 52–70)
67 (60, 51–69)

36 (30, 22–38)
58 (48, 40–58)
53 (45, 36–53)

7.8 [4.4] (7.1–8.6)
53 (34, 27–41)

7.8 [4.0] (71–8.6)
32 (28, 20–36)

8.3 [4.5] (7.5–9.1)
45 (37, 29–46)

3.7 [2.5] (3.3–4.1)
19 (13, 7–17)
3.0 [0.8] (2.8–3.1)

4.2 [2.5] (3.8–4.7)
21 (19, 12–26)
3.2 [0.9] (3.1–3.4)

4.1 [2.6] (3.6–4.6)
21 (18, 11–25)
3.2 [0.9] (3.1–3.4)

Note: The AASM criteria were used when hypertensive primary care patients below 65 years of age were categorized into OSA groups
based on apnoea–hypopnoea index ⬍ 5/h, 5–14.9/h, or ⱖ 15/h.
Key: AHI ⫽ Apnea–hypopnea index; BSAQ ⫽ Berlin Sleep Apnea Questionnaire, CI 95% – 95% confidence interval; ESS – Epworth
sleepiness scale, HAD ⫽ Hospital Anxiety and Depression Scale; n ⫽ numbers; m – mean.

Discussion
The major findings of this study were that more than
one-half of a cohort of hypertensive primary care
patients had objective evidence of OSA. But no relationship between OSA and severity of blood pressure
elevation, or specific comorbid conditions was seen.
Diabetes, depressive symptoms, insomnia, and EDS
were common, but not associated with OSA. Male
gender, BMI ⬎30 kg/m2, snoring, witnessed apnoeas,
and sleep duration ⬎8 hours were significant correlates
of OSA.
Table III. Multivariate regression model for apnoea–
hypopnoea index ⬎15 in hypertensive primary care patients
below 65 years of age (n ⫽ 394).
Variables
Male gender
Body mass index ⬍ 24.9
Body mass index 25–29.9
Body mass index ⬎ 30
Diabetes
Hypercholesterolemia
Snoring
Witnessed apnoeas
Sleep duration ⬎ 8 hours
Perceived health

Odds ratio

95% CI for EXP (B)

1.7
(ref)
1.6
4.0
1.08
1.05
3.9
3.2
3.6
.98

1.05–2.7
(ref)
0.74–3.5
1.8–9.1
0.5–2.1
0.6–1.8
1.3–11.6
1.8–5.7
1.03–12.8
0.7–1.3

OSA in this sample was more common than that
found in community-based Scandinavian and European general populations [3–5] despite our focus on
the occurrence of undiagnosed OSA (e.g. patients
with treated OSA were excluded). This could be
explained by our selection of hypertensive patients
[8]. Sjöström et al. [11] found in a stratified sample
of hypertensive men that 37% had AHI ⬎10. In a
community-based case-control study, Hedner et al.
[12] found AHI ⬎ 10 in 83% of middle-aged patients
with both HT and diabetes. Comparing our data
with those from these studies is difficult, since they
used different cut-off scores for AHI and Hedner’s
subjects also had metabolic syndrome, one of the
best predictors for OSA [13].
Prior studies [20–22] have suggested that OSA is
commonly associated with HT. We found no association between OSA severity and level of blood
pressure elevation or pharmacological treatment, in
contrast to previous studies where a dose–response
relationship was found between night-time blood
pressure and increasing AHI [23]. This may be due
to the fact that our patients were already treated for
HT, mostly successfully. EDS and depressive symptoms, commonly assumed as predictors of OSA [13],
were not associated with OSA although we used

112

A. Broström et al.

validated questionnaires to assess them [16,17]. The
fact that we did not enrol patients from a sleep clinic
might explain the lower occurrence of sleeping difficulties, EDS, and depressive symptoms found compared with other samples [13]. These findings shed
light on the difficulties that GPs have in identifying
patients with OSA in primary care who are in need
of weight reduction or treatment of OSA [24,25].
However, we identified that hypertensive men who
are obese (i.e. BMI ⬎ 30 kg/m2), snore, and report
witnessed apnoeas, as well as long sleep duration (i.e.
⬎ 8 hours) can be suspected to have OSA. Obesity
is common in sleep clinic patients [8,13], and intensive interventions based on low-calorie diets to reduce
weight have been shown to decrease AHI [26], but
long-term results are lacking. Questionnaires, such
as the BSAQ [14,27], focusing on weight gain/obesity, snoring, witnessed apnoeas, and EDS may,
together with simple two-channel recording devices
[28], be suitable in routine screening in primary care
settings. Importantly, results from the BSAQ and the
two channel devices are not comparable to validated
diagnostic tools, such as polygraphy or polysomnography, and need to be more thoroughly evaluated
regarding sensitivity and specificity. Large, welldesigned studies are therefore needed to explore
symptom profiles, clinical characteristics, and different suitable screening procedures for hypertensive
patients with undiagnosed OSA of different severity
levels in primary care settings. Such studies can help
to identify patients who would benefit from referral
to a sleep clinic.
We found that desaturations were highly prevalent (i.e. mean ODI of 32.0) in those with AHI ⬎
15. Hypoxia is an important contributor to CVD in
patients with OSA (i.e. by sympathetic activation
and increased levels of catecholamines, causing
inflammation, arterial stiffness, and atherosclerosis)
[6]. Initiation of continuous positive airway pressure
(CPAP) can eliminate apnoeas and desaturations,
and reduce cardiovascular morbidity and mortality
[29], particularly in patients with severe OSA and
daytime symptoms. Blood pressure reductions after
CPAP have been found, especially in sleepy patients
with frequent desaturations, but also when HT is
severe, untreated, or refractory [30]. However, the
effect of CPAP in hypertensive primary care patients
with OSA, especially those with mild and moderate
OSA, is unknown.
In conclusion, undiagnosed OSA (AHI ⬎ 15) is
common in hypertensive primary care patients. Snoring male patients with elevated BMI, long sleep duration, and witnessed apnoeas should be investigated
for OSA. Future studies should focus on randomized
controlled trials evaluating long-term effects of CPAP
in hypertensive primary care patients with OSA.

Stratifying men and women with different levels of
OSA will strengthen the evidence base for treatment.
Potential confounding factors for CVD, such as obesity, should also be controlled.
Limitations of this study include the crosssectional design, and the lack of a normotensive control group matched for age, gender, and BMI, as well
as the relatively low participation rate. Furthermore,
no objective data regarding sleep were collected, which
means that the occurrence of OSA might have been
even higher since there are difficulties in estimating
sleep onset and wake-up time with polygraphy [28].
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